FDA says initial rejections of new drugs have declined

The FDA has moved to dispel what it characterizes as inaccurate claims that the agency is increasingly rejecting new drugs after an initial review, according to Endpoints News. The dispute traces to a 2027 budget-related report, cited in the outlet’s account, which had been read by some as evidence of a rising rejection trend.

According to Endpoints News, the FDA’s own data show the opposite pattern: initial rejections of new drug applications have declined rather than increased. The agency’s statement, as reported, frames this as a correction of a misreading of the budget document rather than a change in agency policy or review standards.

The story does not specify, beyond what Endpoints News reports, which parties advanced the original claims of rising rejections, nor does it detail the full methodology behind the FDA’s rejection figures. The available material centers on the FDA’s rebuttal and the underlying data point that rejection rates have moved downward over the period in question.

The clarification carries consequence for drug developers who track first-cycle review outcomes when planning clinical and regulatory timelines, and for public perception of how the FDA is handling new drug applications. No further agency action or follow-up report is mentioned in the source material reviewed for this bulletin.